<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Symptomatic <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">gastro-esophageal reflux disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) is a very common disease </plain></SENT>
<SENT sid="1" pm="."><plain>The consequence of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> is not only erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, but also <z:hpo ids='HP_0002043'>esophageal stricture</z:hpo>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and extra-esophageal damage (including the lungs, throat, sinuses, middle ear and teeth) </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> are also identified as major risk factors for <z:hpo ids='HP_0011459'>esophageal carcinoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Therapy with <z:chebi fb="9" ids="16796">melatonin</z:chebi> prevents esophageal injury from acid-pepsin and acid-pepsin-bile exposure in animals, then further studies are required in humans to establish whether a <z:chebi fb="9" ids="16796">melatonin</z:chebi> supplement is able to protect the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> from <z:mpath ids='MPATH_580'>erosions</z:mpath>, Barrett's and <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
</text></document>